Eiger Biopharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.01
- Today's High:
- $1.15
- Open Price:
- $1.12
- 52W Low:
- $0.96
- 52W High:
- $10.021
- Prev. Close:
- $1.17
- Volume:
- 601100
Company Statistics
- Market Cap.:
- $51.57 million
- Book Value:
- 1.255
- Revenue TTM:
- $13.48 million
- Operating Margin TTM:
- -687.78%
- Gross Profit TTM:
- $11.65 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -47.02%
- Return on Equity TTM:
- -151.56%
Company Profile
Eiger Biopharmaceuticals Inc had its IPO on 2014-01-30 under the ticker symbol EIGR.
The company operates in the Healthcare sector and Biotechnology industry. Eiger Biopharmaceuticals Inc has a staff strength of 0 employees.
Stock update
Shares of Eiger Biopharmaceuticals Inc opened at $1.12 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $1.01 - $1.15, and closed at $1.11.
This is a -5.56% slip from the previous day's closing price.
A total volume of 601,100 shares were traded at the close of the day’s session.
In the last one week, shares of Eiger Biopharmaceuticals Inc have slipped by -18.15%.
Eiger Biopharmaceuticals Inc's Key Ratios
Eiger Biopharmaceuticals Inc has a market cap of $51.57 million, indicating a price to book ratio of 0.7598 and a price to sales ratio of 3.5514.
In the last 12-months Eiger Biopharmaceuticals Inc’s revenue was $13.48 million with a gross profit of $11.65 million and an EBITDA of $-92448000. The EBITDA ratio measures Eiger Biopharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Eiger Biopharmaceuticals Inc’s operating margin was -687.78% while its return on assets stood at -47.02% with a return of equity of -151.56%.
In Q4, Eiger Biopharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 19.8%.
Eiger Biopharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-2.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eiger Biopharmaceuticals Inc’s profitability.
Eiger Biopharmaceuticals Inc stock is trading at a EV to sales ratio of 8.355 and a EV to EBITDA ratio of 0.2474. Its price to sales ratio in the trailing 12-months stood at 3.5514.
Eiger Biopharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $120.14 million
- Total Liabilities
- $25.12 million
- Operating Cash Flow
- $21.80 million
- Capital Expenditure
- $233000
- Dividend Payout Ratio
- 0%
Eiger Biopharmaceuticals Inc ended 2023 with $120.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $120.14 million while shareholder equity stood at $55.31 million.
Eiger Biopharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $25.12 million in other current liabilities, 44000.00 in common stock, $-437193000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $25.80 million and cash and short-term investments were $25.80 million. The company’s total short-term debt was $73,641,000 while long-term debt stood at $39.63 million.
Eiger Biopharmaceuticals Inc’s total current assets stands at $117.54 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.75 million compared to accounts payable of $8.98 million and inventory worth $2.85 million.
In 2023, Eiger Biopharmaceuticals Inc's operating cash flow was $21.80 million while its capital expenditure stood at $233000.
Comparatively, Eiger Biopharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.11
- 52-Week High
- $10.021
- 52-Week Low
- $0.96
- Analyst Target Price
- $9.2
Eiger Biopharmaceuticals Inc stock is currently trading at $1.11 per share. It touched a 52-week high of $10.021 and a 52-week low of $10.021. Analysts tracking the stock have a 12-month average target price of $9.2.
Its 50-day moving average was $1.68 and 200-day moving average was $4.94 The short ratio stood at 1.82 indicating a short percent outstanding of 0%.
Around 744.8% of the company’s stock are held by insiders while 6017.8% are held by institutions.
Frequently Asked Questions About Eiger Biopharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company’s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.